Westfield Capital Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-238,400
Closed -$49.4M 258
2021
Q3
$49.4M Buy
238,400
+34,900
+17% +$7.69M 0.3% 122
2021
Q2
$43.2M Buy
203,500
+97,491
+92% +$17.9M 0.26% 131
2021
Q1
$19.2M Buy
+106,009
New +$21.1M 0.12% 174
2013
Q3
Sell
-4,295
Closed -$176K 367
2013
Q2
$176K Buy
+4,295
New +$186K ﹤0.01% 354

Other funds holding NVAX

Westfield Capital Management's NVAX Position: Q4 2021 in Review

Westfield Capital Management sold out of Novavax (NVAX) in Q4 2021, closing a stake of 238,400 shares — an estimated $49.4M sold.

Westfield Capital Management first reported a position in NVAX in Q2 2013 and held it in 4 quarters. The position peaked at $49.4M in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • Westfield Capital Management reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • Westfield Capital Management sold 238,400 Novavax shares in Q4 2021, an estimated $49.4M.
  • Westfield Capital Management first reported a position in Novavax in Q2 2013 and held it in 4 quarters.
  • Westfield Capital Management's Novavax position peaked at $49.4M in Q3 2021.
  • 429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on Westfield Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.